In today’s briefing:
- Wuxi Biologics (2269.HK) 2021 Results – The Highlights and the Concerns
Wuxi Biologics (2269.HK) 2021 Results – The Highlights and the Concerns
- The continuous increase of backlog and CMO projects would provide high visibility and certainty for the growth of Wuxi Biologics (2269 HK) in 2022.
- Given the complex international relations, it is possible that the US may add WuXi Biologics to any sanctions list again in the future, which means large stock price volatility.
- There could be some short-term rally, but due to the lack of clear positive “signals” in the industry, we do not think it means a complete “reversal” for WuXi Biologics.
Before it’s here, it’s on Smartkarma
